Assertion: heterotopic ossification | /r/RelatedTo | flare up symptoms
Facets:
value: in adults
type: TEMPORAL
value: in children
type: LOCATION
value: with ossificans progressiva
type: OTHER
Source sentences:
text: The company is preparing for a 2019 NDA submission to the FDA to seek approval of its lead product candidate, palovarotene, a novel RARI[sup.3] agonist, for the prevention of heterotopic ossification associated with flare up symptoms in adults and children with fibrodysplasia ossificans progressiva.